Guardant Health and Washington University Study Reveals Impact of ctDNA on Addressing Racial Inequities in Therapies
Monday, 3 June 2024, 10:28
Guardant Health and Washington University presented a study at the 2024 ASCO meeting
The study highlighted the importance of ctDNA in addressing racial inequities in the utilization of targeted therapies and enrollment in clinical trials.
Key Takeaways:
- ctDNA plays a crucial role in combating disparities in healthcare.
- Improving access to personalized treatments is essential for health equity.
- Research demonstrates the potential of ctDNA in promoting inclusivity in healthcare strategies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.